{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:38:54Z","timestamp":1793421534746,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A resurgence of interest and investment in the field of gene therapy, driven in large part by advances in viral vector technology, has recently culminated in United States Food and Drug Administration approval of the first gene therapy product targeting a disease caused by mutations in a single gene. This product, LUXTURNA\u2122 (voretigene neparvovec-rzyl; Spark Therapeutics, Inc., Philadelphia, PA), delivers a normal copy of the\n                    <jats:italic>RPE65<\/jats:italic>\n                    gene to retinal cells for the treatment of biallelic\n                    <jats:italic>RPE65<\/jats:italic>\n                    mutation\u2013associated retinal dystrophy, a blinding disease. Many additional gene therapy programs targeting both inherited retinal diseases and other ocular diseases are in development, owing to an improved understanding of the genetic basis of ocular disease and the unique properties of the ocular compartment that make it amenable to local gene therapy. Here we review the growing body of literature that describes both the design and development of ocular gene therapy products, with a particular emphasis on target and vector selection, and chemistry, manufacturing, and controls.\n                  <\/jats:p>","DOI":"10.1007\/s11095-018-2554-7","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T14:15:26Z","timestamp":1545920126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye"],"prefix":"10.1007","volume":"36","author":[{"given":"Gerard A.","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenyi","family":"Shalaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel K. H.","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen M.","family":"Rivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"issue":"6372","key":"2554_CR1","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372):eaan4672.","journal-title":"Science"},{"issue":"21","key":"2554_CR2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","volume":"358","author":"JW Bainbridge","year":"2008","unstructured":"Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"2554_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1089\/hum.2008.107","volume":"19","author":"WW Hauswirth","year":"2008","unstructured":"Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19(10):979\u201390.","journal-title":"Hum Gene Ther"},{"issue":"21","key":"2554_CR4","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240\u20138.","journal-title":"N Engl J Med"},{"issue":"5954","key":"2554_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.1181937","volume":"326","author":"L Naldini","year":"2009","unstructured":"Naldini L. Medicine. A comeback for gene therapy. Science. 2009;326(5954):805\u20136.","journal-title":"Science"},{"issue":"3","key":"2554_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/mt.2012.280","volume":"21","author":"SE Boye","year":"2013","unstructured":"Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther. 2013;21(3):509\u201319.","journal-title":"Mol Ther"},{"issue":"9","key":"2554_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1089\/hum.2009.086","volume":"20","author":"AV Cideciyan","year":"2009","unstructured":"Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009;20(9):999\u20131004.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2554_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","volume":"130","author":"SG Jacobson","year":"2012","unstructured":"Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9\u201324.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2554_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/mt.2009.277","volume":"18","author":"F Simonelli","year":"2010","unstructured":"Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2010;18(3):643\u201350.","journal-title":"Mol Ther"},{"issue":"6","key":"2554_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","volume":"120","author":"F Testa","year":"2013","unstructured":"Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013;120(6):1283\u201391.","journal-title":"Ophthalmology"},{"issue":"120","key":"2554_CR11","doi-asserted-by":"publisher","first-page":"120ra115","DOI":"10.1126\/scitranslmed.3002865","volume":"4","author":"J Bennett","year":"2012","unstructured":"Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, et al. Maguire AM. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4(120):120ra115.","journal-title":"Sci Transl Med"},{"issue":"20","key":"2554_CR12","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JW Bainbridge","year":"2015","unstructured":"Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. 2015;372(20):1887\u201397.","journal-title":"N Engl J Med"},{"issue":"20","key":"2554_CR13","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","volume":"372","author":"SG Jacobson","year":"2015","unstructured":"Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372(20):1920\u20136.","journal-title":"N Engl J Med"},{"issue":"10097","key":"2554_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849\u201360.","journal-title":"Lancet"},{"issue":"9923","key":"2554_CR15","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet. 2014;383(9923):1129\u201337.","journal-title":"Lancet"},{"issue":"Pt B","key":"2554_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ejpb.2014.12.022","volume":"95","author":"M\u00c1 Solin\u00eds","year":"2015","unstructured":"Solin\u00eds M\u00c1, del Pozo-Rodr\u00edguez A, Apaolaza PS, Rodr\u00edguez-Gasc\u00f3n A. Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm. 2015;95(Pt B):331\u201342.","journal-title":"Eur J Pharm Biopharm"},{"issue":"R1","key":"2554_CR17","doi-asserted-by":"publisher","first-page":"R2","DOI":"10.1093\/hmg\/ddx185","volume":"26","author":"GJ Farrar","year":"2017","unstructured":"Farrar GJ, Carrigan M, Dockery A, Millington-Ward S, Palfi A, Chadderton N, et al. Toward an elucidation of the molecular genetics of inherited retinal degenerations. Hum Mol Genet. 2017;26(R1):R2\u2013R11.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2554_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/gim.2015.70","volume":"18","author":"JR Black","year":"2016","unstructured":"Black JR, Clark SJ. Age-related macular degeneration: genome-wide association studies to translation. Genet Med. 2016;18(4):283\u20139.","journal-title":"Genet Med"},{"issue":"5","key":"2554_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/ICU.0b013e32834922d2","volume":"22","author":"AO Khan","year":"2011","unstructured":"Khan AO. Genetics of primary glaucoma. Curr Opin Ophthalmol. 2011;22(5):347\u201355.","journal-title":"Curr Opin Ophthalmol"},{"key":"2554_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/bs.pmbts.2015.04.005","volume":"134","author":"AO Eghrari","year":"2015","unstructured":"Eghrari AO, Riazuddin SA, Gottsch JD. Fuchs corneal dystrophy. Prog Mol Biol Transl Sci. 2015;134:79\u201397.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"2","key":"2554_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cge.12203","volume":"84","author":"SP Daiger","year":"2013","unstructured":"Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet. 2013;84(2):132\u201341.","journal-title":"Clin Genet"},{"key":"2554_CR22","unstructured":"RetNet\u2122 Retinal Information Network. Available from: https:\/\/sph.uth.edu\/retnet\/. Accessed 20 Nov 2018."},{"issue":"2","key":"2554_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1242\/dmm.017913","volume":"8","author":"S Veleri","year":"2015","unstructured":"Veleri S, Lazar CH, Chang B, Sieving PA, Banin E, Swaroop A. Biology and therapy of inherited retinal degenerative disease: insights from mouse models. Dis Model Mech. 2015;8(2):109\u201329.","journal-title":"Dis Model Mech"},{"issue":"9","key":"2554_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.ophtha.2017.04.008","volume":"124","author":"EM Stone","year":"2017","unstructured":"Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology. 2017;124(9):1314\u201331.","journal-title":"Ophthalmology"},{"issue":"4","key":"2554_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/138920211795860107","volume":"12","author":"S Ferrari","year":"2011","unstructured":"Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F. Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics. 2011;12(4):238\u201349.","journal-title":"Curr Genomics"},{"issue":"2","key":"2554_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134\u201343.","journal-title":"Nat Genet"},{"issue":"2","key":"2554_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.molimm.2014.06.032","volume":"61","author":"EC Schramm","year":"2014","unstructured":"Schramm EC, Clark SJ, Triebwasser MP, Raychaudhuri S, Seddon JM, Atkinson JP. Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol Immunol. 2014;61(2):118\u201325.","journal-title":"Mol Immunol"},{"issue":"12","key":"2554_CR28","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/bjo.2006.098426","volume":"90","author":"RB Bhisitkul","year":"2006","unstructured":"Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90(12):1542\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2554_CR29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","volume":"177","author":"IJ Constable","year":"2017","unstructured":"Constable IJ, Lai CM, Magno AL, French MA, Barone SB, Schwartz SD, et al. Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial. Am J Ophthalmol. 2017;177:150\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"10089","key":"2554_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","volume":"390","author":"JS Heier","year":"2017","unstructured":"Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390(10089):50\u201361.","journal-title":"Lancet"},{"issue":"11","key":"2554_CR31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.addr.2006.07.023","volume":"58","author":"C Bloquel","year":"2006","unstructured":"Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev. 2006;58(11):1224\u201342.","journal-title":"Adv Drug Deliv Rev"},{"key":"2554_CR32","first-page":"2344","volume":"13","author":"HC Cheng","year":"2007","unstructured":"Cheng HC, Yeh SI, Tsao YP, Kuo PC. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis. 2007;13:2344\u201352.","journal-title":"Mol Vis"},{"issue":"8","key":"2554_CR33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/gt.2009.50","volume":"16","author":"KC Yoon","year":"2009","unstructured":"Yoon KC, Bae JA, Park HJ, Im SK, Oh HJ, Lin XH, et al. Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model. Gene Ther. 2009;16(8):973\u201381.","journal-title":"Gene Ther"},{"issue":"6","key":"2554_CR34","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1167\/iovs.09-4920","volume":"51","author":"R Gerometta","year":"2010","unstructured":"Gerometta R, Spiga MG, Borras T, Candia OA. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci. 2010;51(6):3042\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"2554_CR35","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/mt.2009.181","volume":"17","author":"D Dalkara","year":"2009","unstructured":"Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther. 2009;17(12):2096\u2013102.","journal-title":"Mol Ther"},{"issue":"1","key":"2554_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ymthe.2016.10.008","volume":"25","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Igarashi T, Miyake K, Kobayashi M, Yaguchi C, Iijima O, et al. Improved intravitreal AAV-mediated inner retinal gene transduction after surgical internal limiting membrane peeling in cynomolgus monkeys. Mol Ther. 2017;25(1):296\u2013302.","journal-title":"Mol Ther"},{"issue":"4","key":"2554_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060218","volume":"8","author":"AR Bruewer","year":"2013","unstructured":"Bruewer AR, Mowat FM, Bartoe JT, Boye SL, Hauswirth WW, Petersen-Jones SM. Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs. PLoS One. 2013;8(4):e60218.","journal-title":"PLoS One"},{"issue":"2","key":"2554_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017140","volume":"6","author":"MC Peden","year":"2011","unstructured":"Peden MC, Min J, Meyers C, Lukowski Z, Li Q, Boye SL, et al. Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter. PLoS One. 2011;6(2):e17140.","journal-title":"PLoS One"},{"issue":"1","key":"2554_CR39","first-page":"GE01","volume":"9","author":"M Ramamoorth","year":"2015","unstructured":"Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01\u20136.","journal-title":"J Clin Diagn Res"},{"issue":"10","key":"2554_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/sj.gt.3302475","volume":"12","author":"S Kachi","year":"2005","unstructured":"Kachi S, Oshima Y, Esumi N, Kachi M, Rogers B, Zack DJ, et al. Nonviral ocular gene transfer. Gene Ther. 2005;12(10):843\u201351.","journal-title":"Gene Ther"},{"issue":"4","key":"2554_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/hum.2011.115","volume":"23","author":"D Delgado","year":"2012","unstructured":"Delgado D, del Pozo-Rodriguez A, Solin\u00eds M\u00c1, Avil\u00e9s-Triqueros M, Weber BH, Fern\u00e1ndez E, et al. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. Hum Gene Ther. 2012;23(4):345\u201355.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"2554_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1023\/A:1023238530504","volume":"20","author":"L Pitkanen","year":"2003","unstructured":"Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res. 2003;20(4):576\u201383.","journal-title":"Pharm Res"},{"key":"2554_CR43","first-page":"124","volume":"11","author":"RA Bejjani","year":"2005","unstructured":"Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis. 2005;11:124\u201332.","journal-title":"Mol Vis"},{"issue":"8","key":"2554_CR44","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1167\/iovs.02-1068","volume":"44","author":"JL Bourges","year":"2003","unstructured":"Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2554_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","volume":"43","author":"I Trapani","year":"2014","unstructured":"Trapani I, Puppo A, Auricchio A. Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res. 2014;43:108\u201328.","journal-title":"Prog Retin Eye Res"},{"issue":"19","key":"2554_CR46","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/gt.2008.78","volume":"15","author":"J Kong","year":"2008","unstructured":"Kong J, Kim SR, Binley K, Pata I, Doi K, Mannik J, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 2008;15(19):1311\u201320.","journal-title":"Gene Ther"},{"issue":"26","key":"2554_CR47","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","volume":"10","author":"A Auricchio","year":"2001","unstructured":"Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet. 2001;10(26):3075\u201381.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2554_CR48","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"R Zufferey","year":"1998","unstructured":"Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873\u201380.","journal-title":"J Virol"},{"issue":"3","key":"2554_CR49","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nm1365","volume":"12","author":"RJ Y\u00e1\u00f1ez-Mu\u00f1oz","year":"2006","unstructured":"Y\u00e1\u00f1ez-Mu\u00f1oz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med. 2006;12(3):348\u201353.","journal-title":"Nat Med"},{"issue":"3","key":"2554_CR50","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1167\/iovs.05-0965","volume":"47","author":"Y Chen","year":"2006","unstructured":"Chen Y, Moiseyev G, Takahashi Y, Ma JX. RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65\n                           \u2212\/\u2212 mice. Invest Ophthalmol Vis Sci. 2006;47(3):1177\u201384.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"22","key":"2554_CR51","doi-asserted-by":"publisher","first-page":"12584","DOI":"10.1073\/pnas.221364198","volume":"98","author":"D Vollrath","year":"2001","unstructured":"Vollrath D, Feng W, Duncan JL, Yasumura D, D'Cruz PM, Chappelow A, et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci U S A. 2001;98(22):12584\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2554_CR52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/hum.2006.17.167","volume":"17","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17(2):167\u201376.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"2554_CR53","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.gt.3300691","volume":"5","author":"MB Reichel","year":"1998","unstructured":"Reichel MB, Ali RR, Thrasher AJ, Hunt DM, Bhattacharya SS, Baker D. Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Ther. 1998;5(8):1038\u201346.","journal-title":"Gene Ther"},{"issue":"24","key":"2554_CR54","doi-asserted-by":"publisher","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","volume":"93","author":"RJ Parks","year":"1996","unstructured":"Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 1996;93(24):13565\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt B","key":"2554_CR55","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejpb.2015.01.009","volume":"95","author":"C Sch\u00f6n","year":"2015","unstructured":"Sch\u00f6n C, Biel M, Michalakis S. Retinal gene delivery by adeno-associated virus (AAV) vectors: strategies and applications. Eur J Pharm Biopharm. 2015;95(Pt B):343\u201352.","journal-title":"Eur J Pharm Biopharm"},{"issue":"17","key":"2554_CR56","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1089\/104303403322542301","volume":"14","author":"AJ Lotery","year":"2003","unstructured":"Lotery AJ, Yang GS, Mullins RF, Russell SR, Schmidt M, Stone EM, et al. Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther. 2003;14(17):1663\u201371.","journal-title":"Hum Gene Ther"},{"issue":"15","key":"2554_CR57","doi-asserted-by":"publisher","first-page":"7651","DOI":"10.1128\/JVI.76.15.7651-7660.2002","volume":"76","author":"GS Yang","year":"2002","unstructured":"Yang GS, Schmidt M, Yan Z, Lindbloom JD, Harding TC, Donahue BA, et al. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol. 2002;76(15):7651\u201360.","journal-title":"J Virol"},{"issue":"6","key":"2554_CR58","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1525-0016(03)00098-4","volume":"7","author":"M Weber","year":"2003","unstructured":"Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, Briot D, et al. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther. 2003;7(6):774\u201381.","journal-title":"Mol Ther"},{"key":"2554_CR59","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coviro.2016.05.001","volume":"18","author":"VJ Madigan","year":"2016","unstructured":"Madigan VJ, Asokan A. Engineering AAV receptor footprints for gene therapy. Curr Opin Virol. 2016;18:89\u201396.","journal-title":"Curr Opin Virol"},{"issue":"3","key":"2554_CR60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/1566523054065057","volume":"5","author":"G Gao","year":"2005","unstructured":"Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5(3):285\u201397.","journal-title":"Curr Gene Ther"},{"issue":"88","key":"2554_CR61","doi-asserted-by":"publisher","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","volume":"3","author":"LH Vandenberghe","year":"2011","unstructured":"Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med. 2011;3(88):88ra54.","journal-title":"Sci Transl Med"},{"issue":"8","key":"2554_CR62","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0042-6989(02)00676-4","volume":"43","author":"A Auricchio","year":"2003","unstructured":"Auricchio A. Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye. Vis Res. 2003;43(8):913\u20138.","journal-title":"Vis Res"},{"issue":"3","key":"2554_CR63","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3):381\u201390.","journal-title":"J Infect Dis"},{"issue":"20","key":"2554_CR64","doi-asserted-by":"publisher","first-page":"11372","DOI":"10.1128\/JVI.01327-07","volume":"81","author":"M Allocca","year":"2007","unstructured":"Allocca M, Mussolino C, Garcia-Hoyos M, Sanges D, Iodice C, Petrillo M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol. 2007;81(20):11372\u201380.","journal-title":"J Virol"},{"issue":"4","key":"2554_CR65","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/jgm.1126","volume":"10","author":"C Lebherz","year":"2008","unstructured":"Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved ocular gene transfer. J Gene Med. 2008;10(4):375\u201382.","journal-title":"J Gene Med"},{"issue":"12","key":"2554_CR66","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1089\/hum.2013.154","volume":"24","author":"A Manfredi","year":"2013","unstructured":"Manfredi A, Marrocco E, Puppo A, Cesi G, Sommella A, Della Corte M, et al. Combined rod and cone transduction by adeno-associated virus 2\/8. Hum Gene Ther. 2013;24(12):982\u201392.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"2554_CR67","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/gt.2011.3","volume":"18","author":"C Mussolino","year":"2011","unstructured":"Mussolino C, della Corte M, Rossi S, Viola F, Di Vicino U, Marrocco E, et al. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther. 2011;18(7):637\u201345.","journal-title":"Gene Ther"},{"issue":"6","key":"2554_CR68","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm1596","volume":"13","author":"JJ Alexander","year":"2007","unstructured":"Alexander JJ, Umino Y, Everhart D, Chang B, Min SH, Li Q, et al. Restoration of cone vision in a mouse model of achromatopsia. Nat Med. 2007;13(6):685\u20137.","journal-title":"Nat Med"},{"issue":"13","key":"2554_CR69","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/hmg\/ddq136","volume":"19","author":"AM Komaromy","year":"2010","unstructured":"Komaromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010;19(13):2581\u201393.","journal-title":"Hum Mol Genet"},{"issue":"7265","key":"2554_CR70","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/nature08401","volume":"461","author":"K Mancuso","year":"2009","unstructured":"Mancuso K, Hauswirth WW, Li Q, Connor TB, Kuchenbecker JA, Mauck MC, et al. Gene therapy for red-green colour blindness in adult primates. Nature. 2009;461(7265):784\u20137.","journal-title":"Nature"},{"issue":"7","key":"2554_CR71","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15(7):445\u201351.","journal-title":"Nat Rev Genet"},{"issue":"22","key":"2554_CR72","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1073\/pnas.0802866105","volume":"105","author":"L Zhong","year":"2008","unstructured":"Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A. 2008;105(22):7827\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2554_CR73","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/mt.2008.269","volume":"17","author":"H Petrs-Silva","year":"2009","unstructured":"Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther. 2009;17(3):463\u201371.","journal-title":"Mol Ther"},{"issue":"12","key":"2554_CR74","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","volume":"121","author":"AT Martino","year":"2013","unstructured":"Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood. 2013;121(12):2224\u201333.","journal-title":"Blood"},{"key":"2554_CR75","doi-asserted-by":"crossref","unstructured":"Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV. In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013;5(189):189ra176.","DOI":"10.1126\/scitranslmed.3005708"},{"issue":"9","key":"2554_CR76","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/mt.2011.62","volume":"19","author":"D Dalkara","year":"2011","unstructured":"Dalkara D, Kolstad KD, Guerin KI, Hoffmann NV, Visel M, Klimczak RR, et al. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol Ther. 2011;19(9):1602\u20138.","journal-title":"Mol Ther"},{"issue":"10","key":"2554_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007467","volume":"4","author":"RR Klimczak","year":"2009","unstructured":"Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Muller cells. PLoS One. 2009;4(10):e7467.","journal-title":"PLoS One"},{"issue":"9","key":"2554_CR78","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1167\/iovs.03-0197","volume":"44","author":"JE Young","year":"2003","unstructured":"Young JE, Vogt T, Gross KW, Khani SC. A short, highly active photoreceptor-specific enhancer\/promoter region upstream of the human rhodopsin kinase gene. Invest Ophthalmol Vis Sci. 2003;44(9):4076\u201385.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"2554_CR79","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1073\/pnas.1118847109","volume":"109","author":"WA Beltran","year":"2012","unstructured":"Beltran WA, Cideciyan AV, Lewin AS, Iwabe S, Khanna H, Sumaroka A, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A. 2012;109(6):2132\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2554_CR80","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1073\/pnas.94.13.6916","volume":"94","author":"JG Flannery","year":"1997","unstructured":"Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997;94(13):6916\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"2554_CR81","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1093\/hmg\/ddr218","volume":"20","author":"LS Carvalho","year":"2011","unstructured":"Carvalho LS, Xu J, Pearson RA, Smith AJ, Bainbridge JW, Morris LM, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet. 2011;20(16):3161\u201375.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2554_CR82","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/mt.2010.149","volume":"18","author":"S Michalakis","year":"2010","unstructured":"Michalakis S, M\u00fchlfriedel R, Tanimoto N, Krishnamoorthy V, Koch S, Fischer MD, et al. Restoration of cone vision in the CNGA3\u2212\/\u2212 mouse model of congenital complete lack of cone photoreceptor function. Mol Ther. 2010;18(12):2057\u201363.","journal-title":"Mol Ther"},{"issue":"14","key":"2554_CR83","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/gt.2008.32","volume":"15","author":"AM Kom\u00e1romy","year":"2008","unstructured":"Kom\u00e1romy AM, Alexander JJ, Cooper AE, Chiodo VA, Glushakova LG, Acland GM, et al. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. Gene Ther. 2008;15(14):1049\u201355.","journal-title":"Gene Ther"},{"issue":"3","key":"2554_CR84","first-page":"637","volume":"39","author":"A Nicoletti","year":"1998","unstructured":"Nicoletti A, Kawase K, Thompson DA. Promoter analysis of RPE65, the gene encoding a 61-kDa retinal pigment epithelium-specific protein. Invest Ophthalmol Vis Sci. 1998;39(3):637\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"18","key":"2554_CR85","doi-asserted-by":"publisher","first-page":"19064","DOI":"10.1074\/jbc.M309881200","volume":"279","author":"N Esumi","year":"2004","unstructured":"Esumi N, Oshima Y, Li Y, Campochiaro PA, Zack DJ. Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem. 2004;279(18):19064\u201373.","journal-title":"J Biol Chem"},{"issue":"7","key":"2554_CR86","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/mt.2011.69","volume":"19","author":"MM Doroudchi","year":"2011","unstructured":"Doroudchi MM, Greenberg KP, Liu J, Silka KA, Boyden ES, Lockridge JA, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther. 2011;19(7):1220\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"2554_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/mt.2014.154","volume":"23","author":"E Mac\u00e9","year":"2015","unstructured":"Mac\u00e9 E, Caplette R, Marre O, Sengupta A, Chaffiol A, Barbe P, et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. Mol Ther. 2015;23(1):7\u201316.","journal-title":"Mol Ther"},{"issue":"8","key":"2554_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012387","volume":"5","author":"WM Aartsen","year":"2010","unstructured":"Aartsen WM, van Cleef KW, Pellissier LP, Hoek RM, Vos RM, Blits B, et al. GFAP-driven GFP expression in activated mouse Muller glial cells aligning retinal blood vessels following intravitreal injection of AAV2\/6 vectors. PLoS One. 2010;5(8):e12387.","journal-title":"PLoS One"},{"issue":"6","key":"2554_CR89","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2174\/156652310793797685","volume":"10","author":"E Ayuso","year":"2010","unstructured":"Ayuso E, Mingozzi F, Bosch F. Production, purification and characterization of adeno-associated vectors. Curr Gene Ther. 2010;10(6):423\u201336.","journal-title":"Curr Gene Ther."},{"issue":"1","key":"2554_CR90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/biomedicines2010080","volume":"2","author":"JF Wright","year":"2014","unstructured":"Wright JF. Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment. Biomedicines. 2014;2(1):80\u201397.","journal-title":"Biomedicines"},{"issue":"5","key":"2554_CR91","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/156652310793180715","volume":"10","author":"JF Wright","year":"2010","unstructured":"Wright JF, Wellman J, High KA. Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr Gene Ther. 2010;10(5):341\u20139.","journal-title":"Curr Gene Ther."},{"issue":"3","key":"2554_CR92","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1089\/hgtb.2016.188","volume":"28","author":"M Schnodt","year":"2017","unstructured":"Schnodt M, B\u00fcning H. Improving the quality of adeno-associated viral vector preparations: the challenge of product-related impurities. Hum Gene Ther Methods. 2017;28(3):101\u20138.","journal-title":"Hum Gene Ther Methods"},{"issue":"1","key":"2554_CR93","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymthe.2005.02.021","volume":"12","author":"JF Wright","year":"2005","unstructured":"Wright JF, Le T, Prado J, Bahr-Davidson J, Smith PH, Zhen Z, et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol Ther. 2005;12(1):171\u20138.","journal-title":"Mol Ther"},{"key":"2554_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.2","volume":"3","author":"N Cl\u00e9ment","year":"2016","unstructured":"Cl\u00e9ment N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev. 2016;3:16002.","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"5","key":"2554_CR95","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/8470","volume":"5","author":"C Summerford","year":"1999","unstructured":"Summerford C, Samulski RJ. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med. 1999;5(5):587\u20138.","journal-title":"Nat Med"},{"key":"2554_CR96","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.omtm.2017.12.004","volume":"9","author":"SA Nass","year":"2018","unstructured":"Nass SA, Mattingly MA, Woodcock DA, Burnham BL, Ardinger JA, Osmond SE, et al. Universal method for the purification of recombinant AAV vectors of differing serotypes. Mol Ther Methods Clin Dev. 2018;9:33\u201346.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1\u20132","key":"2554_CR97","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jviromet.2006.11.019","volume":"140","author":"G Qu","year":"2007","unstructured":"Qu G, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J, et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods. 2007;140(1\u20132):183\u201392.","journal-title":"J Virol Methods"},{"key":"2554_CR98","first-page":"197","volume-title":"Protein formulation and delivery","author":"EY Shalaev","year":"2008","unstructured":"Shalaev EY, Wang W, Gatlin LA. Rational choice of excipients of use in lyophilized formulations. In: McNally EJ, Hastedt JE, editors. Protein formulation and delivery. 2nd ed. Boca Raton: CRC Press; 2008. p. 197\u2013217.","edition":"2"},{"key":"2554_CR99","unstructured":"Singh S, Kolhe P, Wang W, Nema S. Large-scale freezing of biologics. Bioprocess Int. 2009;7(9):32\u201344."},{"key":"2554_CR100","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-4939-2383-0_3","volume-title":"Lyophilized biologics and vaccines: modality-based approaches","author":"C Wu","year":"2015","unstructured":"Wu C, Shamblin S, Varshney D, Shalaev E. Advance understanding of buffer behavior during lyophilization. In: Varshney D, Singh M, editors. Lyophilized biologics and vaccines: modality-based approaches. New York: Springer; 2015. p. 25\u201342."},{"issue":"17","key":"2554_CR101","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/sj.gt.3301527","volume":"8","author":"MA Croyle","year":"2001","unstructured":"Croyle MA, Cheng X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 2001;8(17):1281\u201390.","journal-title":"Gene Ther"},{"issue":"9","key":"2554_CR102","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1128\/JVI.02524-12","volume":"87","author":"B Venkatakrishnan","year":"2013","unstructured":"Venkatakrishnan B, Yarbrough J, Domsic J, Bennett A, Bothner B, Kozyreva OG, et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol. 2013;87(9):4974\u201384.","journal-title":"J Virol"},{"issue":"1","key":"2554_CR103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jviromet.2004.07.007","volume":"122","author":"Q Xie","year":"2004","unstructured":"Xie Q, Hare J, Turnigan J, Chapman MS. Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. J Virol Methods. 2004;122(1):17\u201327.","journal-title":"J Virol Methods"},{"issue":"2","key":"2554_CR104","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.colsurfb.2007.06.027","volume":"60","author":"P Wang","year":"2007","unstructured":"Wang P, Li H, Yang HJ, Wang HB, Lu JH, Zhang Y, et al. Glycerol facilitates the disaggregation of recombinant adeno-associated virus serotype 2 on mica surface. Colloids Surf B: Biointerfaces. 2007;60(2):264\u20137.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"3","key":"2554_CR105","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/sj.mt.6300389","volume":"16","author":"J Bennicelli","year":"2008","unstructured":"Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, Zelenaia O, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther. 2008;16(3):458\u201365.","journal-title":"Mol Ther"},{"issue":"Suppl","key":"2554_CR106","first-page":"S251","volume":"5","author":"J Sommer","year":"2002","unstructured":"Sommer J, Sanftner L, Feng L, Suzuki B, Zhen Z, Powell S, et al. Optimal recovery of AAV-AADC vector from Teflon catheters using Polysorbate 80 or Pluronic F68 (abstract 768). Mol Ther. 2002;5(Suppl):S251.","journal-title":"Mol Ther"},{"key":"2554_CR107","doi-asserted-by":"crossref","unstructured":"Shalaev E, Franks F. Solid-liquid state diagrams in pharmaceutical lyophilisation: crystallization of solutes. In: Levine H, editor. Amorphous food and pharmaceutical systems. London: The Royal Society of Chemistry; 2002. p. 200\u201315.","DOI":"10.1039\/9781847550118-00200"},{"issue":"41","key":"2554_CR108","doi-asserted-by":"publisher","first-page":"10619","DOI":"10.1021\/jp409126p","volume":"117","author":"K Anzo","year":"2013","unstructured":"Anzo K, Harada M, Okada T. Enhanced kinetics of pseudo first-order hydrolysis in liquid phase coexistent with ice. J Phys Chem A. 2013;117(41):10619\u201325.","journal-title":"J Phys Chem A"},{"issue":"5","key":"2554_CR109","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/10837450701481157","volume":"12","author":"BS Bhatnagar","year":"2007","unstructured":"Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505\u201323.","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"2554_CR110","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/jps.21017","volume":"97","author":"BS Bhatnagar","year":"2008","unstructured":"Bhatnagar BS, Pikal MJ, Bogner RH. Study of the individual contributions of ice formation and freeze-concentration on isothermal stability of lactate dehydrogenase during freezing. J Pharm Sci. 2008;97(2):798\u2013814.","journal-title":"J Pharm Sci"},{"issue":"10","key":"2554_CR111","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1351\/pac199163101367","volume":"63","author":"F Franks","year":"1991","unstructured":"Franks F, Hatley RHM. Stability of proteins at subzero temperatures: thermodynamics and some ecological consequences. Pure Appl Chem. 1991;63(10):1367\u201380.","journal-title":"Pure Appl Chem"},{"key":"2554_CR112","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1365-2621.1969.tb10370.x","volume":"34","author":"DB Lund","year":"1969","unstructured":"Lund DB, Fennema OR, Powrie WD. Enzymic and acid hydrolysis of sucrose as influenced by freezing. J Food Sci. 1969;34:378\u201382.","journal-title":"J Food Sci"},{"key":"2554_CR113","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1021\/ar50016a001","volume":"2","author":"RE Pincock","year":"1969","unstructured":"Pincock RE. Reactions in frozen systems. Acc Chem Res. 1969;2:97\u2013103.","journal-title":"Acc Chem Res"},{"key":"2554_CR114","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1021\/ed043p358","volume":"43","author":"RE Pincock","year":"1966","unstructured":"Pincock RE, Kiovsky TE. Kinetics of reactions in frozen solutions. J Chem Educ. 1966;43:358\u201360.","journal-title":"J Chem Educ"},{"issue":"9","key":"2554_CR115","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/jps.21843","volume":"98","author":"JJ Schwegman","year":"2009","unstructured":"Schwegman JJ, Carpenter JF, Nail SL. Evidence of partial unfolding of proteins at the ice\/freeze-concentrate interface by infrared microscopy. J Pharm Sci. 2009;98(9):3239\u201346.","journal-title":"J Pharm Sci"},{"issue":"4","key":"2554_CR116","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11095-010-0343-z","volume":"28","author":"SK Singh","year":"2011","unstructured":"Singh SK, Kolhe P, Mehta AP, Chico SC, Lary AL, Huang M. Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding. Pharm Res. 2011;28(4):873\u201385.","journal-title":"Pharm Res"},{"issue":"2","key":"2554_CR117","first-page":"174","volume":"6","author":"JF Wright","year":"2003","unstructured":"Wright JF, Qu G, Tang C, Sommer JM. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel. 2003;6(2):174\u20138.","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"1","key":"2554_CR118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/hgtb.2016.180","volume":"28","author":"DB Howard","year":"2017","unstructured":"Howard DB, Harvey BK. Assaying the stability and inactivation of AAV serotype 1 vectors. Hum Gene Ther Methods. 2017;28(1):39\u201348.","journal-title":"Hum Gene Ther Methods"},{"key":"2554_CR119","unstructured":"Guidance for FDA Reviewers and Sponsors, Content and Review of Chemistry, Manufacturing and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Food and Drug Administration, Center for Biologics Evaluation and Research. 2008. Available from: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/cellularandgenetherapy\/ucm078694.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.19","volume":"5","author":"S D'Costa","year":"2016","unstructured":"D'Costa S, Blouin V, Broucque F, Penaud-Budloo M, Fran\u00e7ois A, Perez IC, et al. Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol Ther Methods Clin Dev. 2016;5:16019.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"2554_CR121","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/gt.2016.2","volume":"23","author":"EW Neuberger","year":"2016","unstructured":"Neuberger EW, Perez I, Le Guiner C, Moser D, Ehlert T, Allais M, et al. Establishment of two quantitative nested qPCR assays targeting the human EPO transgene. Gene Ther. 2016;23(4):330\u20139.","journal-title":"Gene Ther"},{"issue":"1","key":"2554_CR122","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1525-0016(02)00019-9","volume":"7","author":"JM Sommer","year":"2003","unstructured":"Sommer JM, Smith PH, Parthasarathy S, Isaacs J, Vijay S, Kieran J, et al. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther. 2003;7(1):122\u20138.","journal-title":"Mol Ther"},{"issue":"5","key":"2554_CR123","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1021\/nn102651p","volume":"5","author":"KI Joo","year":"2011","unstructured":"Joo KI, Fang Y, Liu Y, Xiao L, Gu Z, Tai A, et al. Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates. ACS Nano. 2011;5(5):3523\u201335.","journal-title":"ACS Nano"},{"key":"2554_CR124","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.omtm.2017.07.003","volume":"6","author":"A Bennett","year":"2017","unstructured":"Bennett A, Patel S, Mietzsch M, Jose A, Lins-Austin B, Yu JC, et al. Thermal stability as a determinant of AAV serotype identity. Mol Ther Methods Clin Dev. 2017;6:171\u201382.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2554_CR125","unstructured":"U.S. Food and Drug Administration Center for Biologics Evaluation and Research. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs): draft guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM610795.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR126","unstructured":"U.S. Food and Drug Administration Center for Biologics Evaluation and Research. Human gene therapy for retinal disorders: draft guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM610803.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR127","unstructured":"U.S. Food and Drug Administration Center for Biologics Evaluation and Research. Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up: draft guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM610800.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR128","unstructured":"U.S. Food and Drug Administration Center for Biologics Evaluation and Research. Human gene therapy for hemophilia: draft guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM610801.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR129","unstructured":"U.S. Food and Drug Administration Center for Biologics Evaluation and Research. Human gene therapy for rare diseases: draft guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM610802.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR130","unstructured":"U.S. Food and Drug Administration Center for Biologics Evaluation and Research. Long term follow-up after administration of human gene therapy products: draft guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM610797.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR131","unstructured":"European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2018. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2018\/07\/WC500252056.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR132","unstructured":"U.S. Food and Drug Administration Center for Biologics Evaluation and Research. Design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products: guidance for industry. 2015. Available from: https:\/\/www.fda.gov\/downloads\/Guidances\/UCM404087.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR133","unstructured":"European Medicines Agency. ICH considerations -- general principles to address virus and vector shedding. 2009. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002680.pdf. Accessed 20 Nov 2018."},{"key":"2554_CR134","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline on virus and gene therapy vector shedding and transmission. 2009. Available from: http:\/\/www.ich.org\/products\/guidelines\/multidisciplinary\/multidisciplinary-single\/article\/virus-and-gene-therapy-vector-shedding-and-transmission.html. Accessed 20 Nov 2018."},{"key":"2554_CR135","unstructured":"U.S. Food and Drug Administration. Summary basis for regulatory action -- LUXTURNA. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM592083.pdf. Accessed 20 Nov 2018."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-018-2554-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2554-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2554-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:19:36Z","timestamp":1650413976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-018-2554-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,27]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["2554"],"URL":"https:\/\/doi.org\/10.1007\/s11095-018-2554-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,27]]},"assertion":[{"value":"21 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"29"}}